Ozmosi | Protionamide Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Protionamide

Alternative Names: protionamide, prothionamide
Clinical Status: Inactive
Latest Update: 2025-04-01
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: China | Germany | Greece | Hong Kong | India | Korea | Latvia | Lithuania | Romania | Russia | Slovenia | South Africa | Taiwan | Turkey | Ukraine | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Beijing Chest Hospital
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Tuberculosis, Multidrug-Resistant

Phase 1: Tuberculosis

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00042289

 P1026s

N/A

Completed

HIV Infections

2020-09-30

2024-11-27

NCT02128308

 TBPK

P1

Completed

Tuberculosis

2013-12-01

2024-11-27

Primary Endpoints|Treatments

NCT02409290

 STREAM

P3

Completed

Tuberculosis, Multidrug-Resistant

2022-05-13

2024-11-27

Primary Endpoints

Recent News Events

Date

Type

Title

04/01/2024

PubMed

 A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.

01/24/2024

PubMed

 Development, Validation, and Clinical Application of an Ultra-High-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for the Determination of 10 Antituberculosis Drugs in Human Serum.

01/17/2024

PubMed

 Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions